20/20 Biolabs is trading 7.73% up now at $0.56 after investors continued assessing its August 17 earnings report.
- Second-quarter revenue rose 36.5% year over year to $0.73 million, while gross margin expanded to 41.7% from 30.5%.
- Net loss widened to $1.51 million.
- Gains also align with stronger biotechnology-sector sentiment, including positive cancer-vaccine trial news.